Melanoma under 40

By Carole Renouf
17 November 2016
I spent a morning in clinic with one of MIA’s surgeons about a month ago. As each of her patients arrived, she inquired whether they would mind the CEO sitting in on their appointment because the CEO wanted to learn more about the experience of patients. Every single patient consented to having me present. They ranged from old to young, male to female, early to advanced melanoma and it was very moving for me to spend some time with them as they received everything from the worst news to the best. All the people with melanoma I met that day have stayed with me, but none more so than the young ones (under 40). It was the statistic that melanoma is the most common cancer in 15-39 year old Australians that really persuaded me to take this job.
A few years ago, when I was in a previous role, one of my proudest initiatives was the work we did reaching out to young women, those who got breast cancer in their 20s and 30s.
The impact of cancer on young lives is ferocious and wide-ranging. This is not to diminish in any way its significant impact on older lives, but when you are under 40 the experience of cancer tends to take more away across more aspects of your life and over a longer time. Also, as cancer services tend to be geared towards older people, you are likely to find less help and support suited to your needs and life stage.
The qualitative research that was done into breast cancer in young women revealed that the disease, diagnosis and treatment impacted issues as critical as future employment and career, finances, fertility, relationships and sexuality and self-image. If you would like to see footage from the press conference with affected young women, click here.
To my knowledge, no such research has yet been done in melanoma in Australia. Melanoma is the most common cause of cancer death in 20-39 year olds. In contrast to breast cancer, melanoma strikes both men and women (slightly more men) and therefore must assuredly involve additional issues to breast cancer. Yet, there is no body of evidence as to what these are, nor how to address them.
As we head towards 2017, I have set myself the goal of gathering the evidence from young Australians affected by melanoma of its impact on their lives and of any unmet needs they may have. This may mean a shift in the way we and others provide services.
For example, over 90% of melanoma – if caught early – is curable through surgery, so surgery remains a dominant treatment modality. A famous surgeon once said, “If you can’t cut it out, it’s not real” - yet studies show that psychosocial distress is very real in at least 30% of melanoma patients and I suspect even more real in the young. So is there an unmet need for more psychosocial support for under 40s affected by melanoma, for example?
If you’d like to share your experience and help me gather the evidence about the impact of melanoma on young Australians, please contact us at projectyoung@melanoma.org.au for a personal interview. Your contribution would be greatly appreciated.

Dr James Wilmott awarded for outstanding cancer research
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.

Community invests in MIA's new trial
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.

New trial giving options
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.

Melanoma research summary from ASCO
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.

Updated privacy policy
We value your privacy and want you to be familiar with how we collect, use and disclose your information.

Can cognitive technology assist with melanoma identification?
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.

'4 Questions With...' Series
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.

Stop the Spread campaign shortlisted
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.

A meeting of the minds
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.

MIA's Dermatology services expanded
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.

5 Minutes with Maria Gonzalez
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.

Melanoma eBook to educate GPs
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.

5 Minutes with Dr Scot Ebbinghaus
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.

Opdivo available on PBS for advanced melanoma patients
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.

5 Minutes with Dr Louise Jackett
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.

MIA patient's plight highlighted in ABC series
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.

Recruiting: Pregnancy and moles study
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.

The role of radiotherapy in melanoma
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.

Australian melanoma rates take the silver – and that's good news
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.